Korean J Gastroenterol.  2018 Dec;72(6):286-294. 10.4166/kjg.2018.72.6.286.

Female Gender is a Poor Predictive Factor of Functional Dyspepsia Resolution after Helicobacter pylori Eradication: A Prospective, Multi-center Korean Trial

  • 1Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
  • 2Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. nayoungkim49@empas.com
  • 3Department of Internal Medicine, College of Medicine, Chungbuk National University, Cheongju, Korea.
  • 4Digestive Disease Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
  • 5Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.
  • 6Department of Internal Medicine, Eulji University School of Medicine, Seoul, Korea.
  • 7Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
  • 8Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
  • 9Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
  • 10Department of Internal Medicine and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • 11Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
  • 12Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea.
  • 13Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • 14Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Korea.


The predictive factors of functional dyspepsia (FD) remain controversial. Therefore, we sought to investigate symptom responses in FD patients after Helicobacter pylori (H. pylori) eradication and used predictive factor analysis to identify significant factors of FD resolution at one-year after commencing eradication therapy.
This prospective, multi-center clinical trial was performed on 65 FD patients that met Rome III criteria and had H. pylori infection. Symptom responses and factors that predicted poor response were determined by analysis one year after commencing H. pylori eradication therapy.
A total of 63 patients completed the one-year follow-up. When an eradication success group (n=60) and an eradication failure group (n=3) were compared with respect to FD response rate at one year, results were as follows; complete response 73.3% and 0.0%, satisfactory response 1.7% and 0.0%, partial response 10.0% and 33.3%, and refractory response 15.0% and 66.7%, respectively (p=0.013). Univariate analysis showed persistent H. pylori infection (p=0.021), female gender (p=0.025), and medication for FD during the study period (p=0.013) were associated with poor FD response at one year. However, age, smoking, alcohol consumption, and underlying disease were not found to affect response. Finally, multivariate analysis showed that female gender (OR, 4.70; 95% CI, 1.17-18.88) was the sole independent risk factor of poor FD response at one year after commencing H. pylori eradication therapy.
Female gender was found to predict poor response in FD patients despite H. pylori eradication. Furthermore, successful H. pylori eradication appears to be associated with FD improvement, but the number of non-eradicated patients was too small to conclude.


Helicobacter pylori; Dyspepsia; Female; Symptom assessment

MeSH Terms

Alcohol Drinking
Follow-Up Studies
Helicobacter pylori*
Multivariate Analysis
Prospective Studies*
Risk Factors
Symptom Assessment


  • Fig. 1 Flowchart of participants. H. pylori, Helicobacter pylori.


1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006; 130:1466–1479.
2. Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016; 150:1380–1392.
3. Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 2006; 12:2661–2666.
4. Jung HK, Keum BR, Jo YJ, et al. Diagnosis of functional dyspepsia: a systematic review. Korean J Gastroenterol. 2010; 55:296–307.
5. Kim SE, Park HK, Kim N, et al. Prevalence and risk factors of functional dyspepsia: a nationwide multicenter prospective study in Korea. J Clin Gastroenterol. 2014; 48:e12–e18.
6. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter. 2007; 12:541–546.
7. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol Suppl. 1996; 215:38–47.
8. Du LJ, Chen BR, Kim JJ, Kim S, Shen JH, Dai N. Helicobacter pylori eradication therapy for functional dyspepsia: systematic review and meta-analysis. World J Gastroenterol. 2016; 22:3486–3495.
9. Jodaki A, Sahraie A, Yasemi M, Peyman H, Yasemi MR, Hemati K. Helicobacter pylori eradication effect on patients with functional dyspepsia symptoms. Minerva Gastroenterol Dietol. 2016; 62:148–154.
10. Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015; 149:340.e2–349.e2.
11. Kim SE, Park YS, Kim N, et al. Effect of Helicobacter pylori eradication on functional dyspepsia. J Neurogastroenterol Motil. 2013; 19:233–243.
12. Holtmann G, Kutscher SU, Haag S, et al. Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia; a randomized, double-blind placebo-controlled crossover study. Dig Dis Sci. 2004; 49:672–679.
13. Lee JY, Kim N, Park KS, et al. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial. BMC Gastroenterol. 2016; 16:79.
14. Song KH, Jung HK, Min BH, et al. Development and validation of the Korean Rome III questionnaire for diagnosis of functional gastrointestinal disorders. J Neurogastroenterol Motil. 2013; 19:509–515.
15. Hong SJ, Sung IK, Kim JG, et al. Failure of a randomized, double-blind, placebo-controlled study to evaluate the efficacy of H. pylori eradication in H. pylori-infected patients with functional dyspepsia. Gut Liver. 2011; 5:468–471.
16. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther. 2004; 19:643–654.
17. Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012; 36:3–15.
18. Miwa H, Ghoshal UC, Fock KM, et al. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012; 27:626–641.
19. Nan J, Zhang L, Zhu F, et al. Topological alterations of the intrinsic brain network in patients with functional dyspepsia. J Neurogastroenterol Motil. 2016; 22:118–128.
20. Choi YJ, Kim N, Kim J, Lee DH, Park JH, Jung HC. Upregulation of vanilloid receptor-1 in functional dyspepsia with or without Helicobacter pylori infection. Medicine (Baltimore). 2016; 95:e3410.
21. Yamawaki H, Futagami S, Shimpuku M, et al. Leu72Met408 polymorphism of the ghrelin gene is associated with early phase of gastric emptying in the patients with functional dyspepsia in Japan. J Neurogastroenterol Motil. 2015; 21:93–102.
22. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64:1353–1367.
23. Massarrat S. Unacceptability of Kyoto global consensus report on Helicobacter pylori gastritis. Arch Iran Med. 2016; 19:527–528.
24. Chen Q, Lu H. Kyoto global consensus report on Helicobacter pylori gastritis and its impact on Chinese clinical practice. J Dig Dis. 2016; 17:353–356.
25. Zhao B, Zhao J, Cheng WF, et al. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta-analysis of randomized controlled studies with 12-month follow-up. J Clin Gastroenterol. 2014; 48:241–247.
26. Kim YJ, Chung WC, Kim BW, et al. Is Helicobacter pylori associated functional dyspepsia correlated with dysbiosis? J Neurogastroenterol Motil. 2017; 23:504–516.
27. Ang TL, Fock KM, Teo EK, et al. Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study. J Gastroenterol. 2006; 41:647–653.
28. Kawakubo H, Tanaka Y, Tsuruoka N, et al. Upper gastrointestinal symptoms are more frequent in female than male young healthy Japanese volunteers as evaluated by questionnaire. J Neurogastroenterol Motil. 2016; 22:248–253.
29. Lorena SL, Tinois E, Brunetto SQ, Camargo EE, Mesquita MA. Gastric emptying and intragastric distribution of a solid meal in functional dyspepsia: influence of gender and anxiety. J Clin Gastroenterol. 2004; 38:230–236.
30. Winthorst WH, Post WJ, Meesters Y, Penninx BW, Nolen WA. Seasonality in depressive and anxiety symptoms among primary care patients and in patients with depressive and anxiety disorders; results from the Netherlands study of depression and anxiety. BMC Psychiatry. 2011; 11:198.
31. Kim YS, Kim N, Kim GH. Sex and gender differences in gastroesophageal reflux disease. J Neurogastroenterol Motil. 2016; 22:575–588.
32. Choi YJ, Park YS, Kim N, et al. Gender differences in ghrelin, nociception genes, psychological factors and quality of life in functional dyspepsia. World J Gastroenterol. 2017; 23:8053–8061.
33. Lacy BE, Yu J, Crowell MD. Medication risk-taking behavior in functional dyspepsia patients. Clin Transl Gastroenterol. 2015; 6:e69.
34. Hsu YC, Liou JM, Liao SC, et al. Psychopathology and personality trait in subgroups of functional dyspepsia based on Rome III criteria. Am J Gastroenterol. 2009; 104:2534–2542.
35. Park B, Kim J. Oral contraceptive use, micronutrient deficiency, and obesity among premenopausal females in Korea: the necessity of dietary supplements and food intake improvement. PLoS One. 2016; 11:e0158177.
36. Hwang JJ, Lee DH, Lee AR, et al. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication. World J Gastroenterol. 2015; 21:5568–5574.
37. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter. 2010; 15:38–45.
Full Text Links
  • KJG
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr